These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 15902366

  • 1. [The coagulation cascade--clinical implications].
    Langer H, Gawaz M.
    Herz; 2005 May; 30(3):170-5. PubMed ID: 15902366
    [Abstract] [Full Text] [Related]

  • 2. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
    Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, Collet JP, Steinhubl SR, Montalescot G.
    Arch Intern Med; 2007 Dec 10; 167(22):2423-30. PubMed ID: 18071163
    [Abstract] [Full Text] [Related]

  • 3. Emerging anticoagulants: mechanism of action and future potential.
    Klement P, Rak J.
    Vnitr Lek; 2006 Mar 10; 52 Suppl 1():119-22. PubMed ID: 16637459
    [Abstract] [Full Text] [Related]

  • 4. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E, Lakhani M, Marmur JD.
    J Invasive Cardiol; 2005 Aug 10; 17(8):416-21. PubMed ID: 16079447
    [Abstract] [Full Text] [Related]

  • 5. Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study.
    Schlitt A, Hamilton K, Maegdefessel L, Dahm M, Theis C, Eichler M, Brockmann O, Steinseifer U, Hauroeder B, Hitzler WE, Rupprecht HJ.
    J Heart Valve Dis; 2006 Nov 10; 15(6):809-14. PubMed ID: 17152789
    [Abstract] [Full Text] [Related]

  • 6. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.
    Int Angiol; 2008 Jun 10; 27(3):176-92. PubMed ID: 18506123
    [Abstract] [Full Text] [Related]

  • 7. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB, Goodman SG, Dabbous OH, Agnelli G, GRACE Investigators.
    Am Heart J; 2007 Jun 10; 153(6):960-9. PubMed ID: 17540196
    [Abstract] [Full Text] [Related]

  • 8. Low-molecular weight heparins in percutaneous coronary interventions: current concepts, problems, and perspectives.
    Graf J, Janssens U.
    Curr Pharm Des; 2004 Jun 10; 10(4):375-86. PubMed ID: 14965199
    [Abstract] [Full Text] [Related]

  • 9. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL, Chen J, Qiao SB, Guo YL, Wu YJ, Dai J, Yuan JQ, Qin XW, Yang YJ, Gao RL.
    Chin Med J (Engl); 2006 Mar 05; 119(5):355-9. PubMed ID: 16542576
    [Abstract] [Full Text] [Related]

  • 10. Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial.
    Melloni C, Fier I, Roach J, Kosinski AS, Broderick S, Sigmon K, Myles S, Becker RC, Rao SV, EMINENCE Investigators.
    Am Heart J; 2009 Nov 05; 158(5):726-33. PubMed ID: 19853689
    [Abstract] [Full Text] [Related]

  • 11. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.
    Semin Thromb Hemost; 2008 Feb 05; 34(1):58-73. PubMed ID: 18393143
    [Abstract] [Full Text] [Related]

  • 12. Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants.
    Montalescot G, Walenga JM.
    Clin Appl Thromb Hemost; 2009 Feb 05; 15(2):183-96. PubMed ID: 19117960
    [Abstract] [Full Text] [Related]

  • 13. Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome.
    White H.
    Clin Appl Thromb Hemost; 2014 Jul 05; 20(5):516-23. PubMed ID: 23344993
    [Abstract] [Full Text] [Related]

  • 14. Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention.
    Garg R, Uretsky BF, Lev EI.
    Catheter Cardiovasc Interv; 2007 Sep 05; 70(3):388-406. PubMed ID: 17722043
    [Abstract] [Full Text] [Related]

  • 15. The safety of heparins in end-stage renal disease.
    Sonawane S, Kasbekar N, Berns JS.
    Semin Dial; 2006 Sep 05; 19(4):305-10. PubMed ID: 16893408
    [Abstract] [Full Text] [Related]

  • 16. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
    Vilahur G, Casaní L, Badimon L.
    Thromb Haemost; 2007 Sep 05; 98(3):662-9. PubMed ID: 17849057
    [Abstract] [Full Text] [Related]

  • 17. Heparin and low-molecular-weight heparin.
    Gray E, Mulloy B, Barrowcliffe TW.
    Thromb Haemost; 2008 May 05; 99(5):807-18. PubMed ID: 18449410
    [Abstract] [Full Text] [Related]

  • 18. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM, Mewhort-Buist TA, Berry LR, Chan AK.
    Thromb Haemost; 2009 Jul 05; 102(1):62-8. PubMed ID: 19572069
    [Abstract] [Full Text] [Related]

  • 19. Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options.
    Rothman MT.
    Nat Clin Pract Cardiovasc Med; 2005 Sep 05; 2(9):465-74. PubMed ID: 16265587
    [Abstract] [Full Text] [Related]

  • 20. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
    Maegdefessel L, Schlitt A, Faerber J, Bond SP, Messow CM, Buerke M, Raaz U, Werdan K, Muenzel T, Weiss C.
    Med Klin (Munich); 2008 Sep 15; 103(9):628-32. PubMed ID: 18813885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.